Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer

Cancer of the Prostate Clinical Trial

Official title:

Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01897207
• Other study ID #: SG226_02
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: June 26, 2013
• Last updated: August 14, 2015
• Start date: November 2002
• Est. completion date: October 2011

Study information

• Verified date: August 2015
• Source: Cantonal Hospital of St. Gallen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of this trial is to assess the response rate, the feasibility and toxicity of the treatment with antigen loaded Dendritic Cell Vaccination in Prostate Cancer patients. Furthermore we want to investigate biological responses by measuring markers of in-vivo and ex-vivo immunomodulation.

Description:

Dendritic cell (DC)-based immunotherapy is a promising approach to augment tumor antigen-specific T cell responses in cancer patients. However, tumor escape with down-regulation or complete loss of target antigens may limit the susceptibility of tumor cells to the immune attack. Concomitant generation of T cell responses against several immunodominant antigens may circumvent this potential drawback. In this phase I/II clinical trial, the investigators determined the immunostimulatory capacity of autologous DC pulsed with multiple T cell epitopes derived from four different prostate-specific antigens in patients with advanced hormone-refractory prostate cancer. Autologous DC of HLA-A*0201-positive patients are loaded with antigenic peptides derived from prostate stem cell antigen, prostatic acid phosphatase, prostate-specific membrane antigen, and prostate-specific antigen. A strict quality control concerning the expression of surface markers and the migratory capacity of the DC secured optimal stimulatory capacity. DC were applied intradermally six times at biweekly intervals followed by monthly booster injections. Tolerability and PSA response will be investigated. Antigen-specific immune responses will be quantified.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: October 2011
• Est. primary completion date: August 2009
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• histologically or cytologically proven prostatic carcinoma

• proven hormonal resistance: tumor progression after orchiectomy or during treatment with hormonal agents. Patients treated with antiandrogens, such as flutamide (Flucinom) or bicalutamide (Casodex), should have been discontinued the drug 6 weeks prior to the trial entry followed by no tumor response within this 6 weeks

• not amenable to curative therapy

• patients with measurable and non-measurable disease may be included. Bone lesions only are considered to be non-measurable

• two consecutive increases of prostate-specific antigen (PSA) should be documented over a previous reference value (N°1). The first increase in PSA (N°2) should occur a minimum of one week from the reference value and be confirmed (N°3). If this value is less than the previous value, the patient is still eligible if the next PSA(N°4) is found to be higher than the second PSA. Serum levels of prostate-specific antigen must be at least 10 microg/l

• Previous radiotherapy is allowed if it has been stopped 4 weeks or more before the trial treatment and did not involve lesions used to evaluate activity of the trial drugs

• one previous chemotherapy (including Estracyt) is allowed, but the chemotherapy should have been stopped at least 6 weeks before study entry

• age >18 years

• performance status 0,1,2 (ECOG, Appendix I)

• no concurrent therapy with steroids

• no uncontrolled infections

• live expectancy more than 3 months

• Human leukocyte antigen (HLA)-Type has to be HLA*A201

• neutrophile count >1500/microl and thrombocytes >100 000/microl

• creatinine <1.5 of upper normal level

• adequate liver function with bilirubin <2 of upper normal level, alanine aminotransferase (ALAT) and aspartate transamionase (ASAT) < 3 x upper normal level

• absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

• before patient registration/randomization, informed consent must be given according to good clinical practice (GCP), and national/local regulations

Exclusion Criteria:

• serious concomitant disease (cardiac, pulmonary and others)

• brain metastasis

• previous splenectomy or radiotherapy to the spleen

• concurrent therapy with immunosuppressive drugs

• chronic immunosuppression (includes transplantation or HIV-infection) HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) (test required) or any other severe uncontrolled infection other neoplastic diseases except: curatively treated basal cell or squamous cell carcinoma of the skin or relapse free for more than 5 years after curative treatment of a neoplasm

• treatment with other investigational drugs during the last month

• severe autoimmune disease

• chemotherapy, radiotherapy or immunotherapy less than 6 weeks before study entry

• Ejection fraction (measured by echocardiography) < 40%

Related Conditions & MeSH terms

• Cancer of the Prostate
• Prostatic Neoplasms

Intervention

Biological:
• Dendritic cell application
S.C. injection of peptide pulsed autologous dendritic cells

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Cantonal Hospital of St. Gallen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	tolerability and toxicity and feasibility of this regimen		directly after vaccination (within 24 h)
Primary	response rate or PSA response in non measurable disease	The given time frame reflects the minimum of PSA values. From Patients receiving more than 6 DC vaccination every 4 weeks PSA was determined until the end of DC vaccination (longest was one and a half year).	Change from baseline in serum PSA at 6, 10 and 12 weeks
Primary	ex-vivo immunomodulation	Peripheral blood mononuclear cells (PBMC) isolation and in-vitro restimulation. Measurement of antigen specific immune responses.	before vaccination, after 6, 10, 12, and up to 85 weeks
Secondary	pain relief	Changes in pain intensity will be assessed by summarizing score items 9 and 19 of the European Organisation for Research and Treatment of Cancer (EORTC)quality of life questionnaire (QLQ-C30) quality. Additionally, analgesic consumption will be rated by a pain treatment score (PTS).	Change from baseline in pain relief at 2, 4, 6, 8, 10 and 12 weeks
Secondary	Overall survival		From first date of treatment until dead